Drug profile · INN
rasburicase
FASTURTEC
rasburicase (FASTURTEC) is a uric acid oxidative enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — rasburicase
- US status
- approved
- Class
- Various (V03)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
rasburicase (FASTURTEC) is a uric acid oxidative enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Uric acid oxidative enzyme
Primary target: Uric acid
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rasburicase?
rasburicase (FASTURTEC) is a uric acid oxidative enzyme. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for rasburicase?
FASTURTEC is a marketed brand name for rasburicase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rasburicase?
rasburicase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.